Effects of a P2Y(12) receptor antagonist on the response of equine platelets to ADP. Comparison with human platelets.

The research article discusses a study on the effects of a P2Y(12) receptor antagonist on platelets in horses, as compared to its effects on human platelets. The study explores the possibility of using this antagonist for the treatment of thrombotic conditions in horses, taking into consideration the differences in platelet response between the two species.

Research Background and Objective

• The study was conducted in response to detected susceptibility of horses to platelet-related medical conditions. As the behaviors of equine platelets are different from human platelets, it’s paramount to validate information from human platelets within a horse-centric context.
• The objective of the research was to explore the impact of the P2Y(12) antagonist, AR-C67085, on equine platelets and compare it to the effect it has on human platelets. This was to assist in determining the potential use of the antagonist in treating thrombotic conditions in horses.

Research Methodology and Key Findings

• To measure the rate and final extent of platelet aggregation, researchers used a technique called turbidimetric aggregometry. The process of platelet aggregation is mediated by ADP involving both P2Y(1) and P2Y(12) receptors on platelets.
• Researchers found that the rate of aggregation of horse platelets was more susceptible to inhibition by the P2Y(12) antagonist, AR-C67085, than that of human platelets. They analyzed aggregation profiles, concentration-response curves, and pA(2) values to come to this conclusion.

Interpretation and Further Implications

• The difference in response to the P2Y(12) antagonist found between horses and humans could be due to differences in the relative numbers of P2Y(1) and P2Y(12) receptors in their bodies, or variations in intracellular signalling pathways.
• These findings are significant as they prompt consideration from equine clinicians. Care must be taken when using P2Y(12) antagonists for treating thrombotic conditions in horses, given the discovered differences in platelet response compared to humans.